Global Health Solutions to Pursue Orphan Indication Following Successful Preclinical Data for Ophthalmologic Drug Candidate

LOS ANGELES, Feb. 22, 2018 /PRNewswire/ -- Global Health Solutions, LLC, has announced successful in-vitro and in-vivo data for OV-02, a unique biocidal ointment intended to treat and prevent ocular colonization of viruses, such as those that lead to shingles of the eye and pink eye. OV-02 is a unique, proprietary fusion of biocides in an extended-release matrix that is both pH neutral and non-irritating. The company has commenced work on orphan drug submission for shingles of the eye, with plans to submit for FDA IND clearance in Q3.

Global Health Solutions Founder and Chief Executive Officer, Bradley Burnam, states: "Our primary skillset lies in the creation of unique delivery systems that fuse liquid active ingredients with gentle, oil-based carriers. In the case of OV-02, we have successfully fused powerful, liquid biocides with a lipid carrier, and, according to data, eliminated localized ocular irritation while nearly mimicking the pH of teardrops."

Global Health Solutions Chief Medical Officer, Neil Ghodadra, MD, states: "Shingles of the eye, or ophthalmic herpes zoster, is a known, preventable cause of blindness affecting ten to twenty percent of shingles patients. Ophthalmic herpes zoster has few known treatment options other than powerful steroids and oral antivirals. OV-02 stands to provide physicians and patients an effective option for early intervention and blindness prevention."

Global Health Solutions, LLC, is a 'concept-to-approval' research and development organization focused on novel products formulated using unique delivery systems. The company's proprietary technologies are used every day by world-leading healthcare institutions to reduce the human and economic costs of skin disease, chronic wounds, and infection.

Contact:
Global Health Solutions, LLC
info@globalhealthrx.com
706-844-1025

Forward Looking Statements Disclaimer: The statements contained herein may include prospects, statements of future expectations, and other forward-looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance, or events may differ materially from those expressed or implied in such forward-looking statements.

View original content with multimedia:http://www.prnewswire.com/news-releases/global-health-solutions-to-pursue-orphan-indication-following-successful-preclinical-data-for-ophthalmologic-drug-candidate-300602557.html

SOURCE Global Health Solutions

Back to news